Naveen Pemmaraju MD

Myeloproliferative Disorder Hematology-Oncology

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Pemmaraju is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pemmaraju's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
University of Arkansas For Medical Sciences College of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2008 - 2028
OK State Medical License 2020 - 2021
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Start of enrollment: 2014 Dec 18
COMPLETED
PHASE2
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2019 Sep 09
COMPLETED
PHASE1
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy Start of enrollment: 2020 Dec 15
WITHDRAWN
PHASE1, PHASE2

Publications & Presentations

PubMed

Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.
Jayastu Senapati, Hiam M Abdel-Salam, Vladislav D Jdanov, Sanam Loghavi, Ashley Woodson
Cancer. 2026-10-01
Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia.
Mahesh Swaminathan, Hussein A Abbas, Michael Roth, Michelle A T Hildebrandt, Warren Fingrut
Clinical Lymphoma, Myeloma & Leukemia. 2026-09-01
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
Hannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, Janice Chen, Arturo Olguin
Leukemia. 2026-09-01

Journal Articles

Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor Therapy
Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Blood
International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Thomas S Uldrick..., Blood

Abstracts/Posters

Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Naveen Pemmaraju, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Myeloproliferative Neoplasm (MPN) Patient Online Questionnaire: Assessing PatientsÍ Disease Knowledge in a Rare Hematologic Malignancy in the Modern Digital Informatio...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

Panel Discusses Key Diagnostic Standards for MyelofibrosisMay 2024
L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-Induced HyperbilirubinemiaFebruary 2018
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017

Press Mentions

MD Anderson Unveils Breakthroughs in Blood Cancer TreatmentDecember 9th, 2025
Immunotherapy-Linked ADC Offers Hope for Hard-to-Treat Blood CancersDecember 8th, 2025
ASH 2025: New Data Highlights Promise of Pivekimab Sunirine in Two Aggressive Blood Cancers December 7th, 2025